A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)

The P2Y12 receptor inhibitors, especially clopidogrel, are common antiplatelet drugs used for the prevention of recurrent adverse cardiovascular events among patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Several factors may affect the effectiveness...

Full description

Saved in:

Bibliographic Details
Main Author:	Ak-Kaif, Mohammed Ahmed Imran
Format:	Thesis
Language:	English
Published:	2023
Subjects:	RS1-441 Pharmacy and materia medica
Online Access:	http://eprints.usm.my/60515/1/Pages%20from%20MOHAMMED%20AHMED%20IMRAN%20AK-KAIF%20-%20TESIS.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.60515
record_format	uketd_dc
spelling	my-usm-ep.605152024-05-03T00:33:38Z A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI) 2023-06 Ak-Kaif, Mohammed Ahmed Imran RS1-441 Pharmacy and materia medica The P2Y12 receptor inhibitors, especially clopidogrel, are common antiplatelet drugs used for the prevention of recurrent adverse cardiovascular events among patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Several factors may affect the effectiveness of antiplatelet therapy, including genetic variations in CYP450 enzymes. Loss of function (LOF) carriers of the CYP2C19 gene are associated with the decreased metabolism of clopidogrel into active metabolites via CYP2C19 enzyme, leading to decreased platelet inhibition. This causes an increased risk of recurrent cardiovascular events. Drug regulatory authorities suggested using alternative P2Y12 inhibitor, which is ticagrelor. Therefore, this study aims to investigate the adverse effects, and CYP2C19 genetic variations of clopidogrel and ticagrelor treatment among CAD patients undergoing PCI. 2023-06 Thesis http://eprints.usm.my/60515/ http://eprints.usm.my/60515/1/Pages%20from%20MOHAMMED%20AHMED%20IMRAN%20AK-KAIF%20-%20TESIS.pdf application/pdf en public phd doctoral Universiti Sains Malaysia Pusat Pengajian Sains Farmasi (School of Pharmacy)
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	RS1-441 Pharmacy and materia medica
spellingShingle	RS1-441 Pharmacy and materia medica Ak-Kaif, Mohammed Ahmed Imran A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
description	The P2Y12 receptor inhibitors, especially clopidogrel, are common antiplatelet drugs used for the prevention of recurrent adverse cardiovascular events among patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Several factors may affect the effectiveness of antiplatelet therapy, including genetic variations in CYP450 enzymes. Loss of function (LOF) carriers of the CYP2C19 gene are associated with the decreased metabolism of clopidogrel into active metabolites via CYP2C19 enzyme, leading to decreased platelet inhibition. This causes an increased risk of recurrent cardiovascular events. Drug regulatory authorities suggested using alternative P2Y12 inhibitor, which is ticagrelor. Therefore, this study aims to investigate the adverse effects, and CYP2C19 genetic variations of clopidogrel and ticagrelor treatment among CAD patients undergoing PCI.
format	Thesis
qualification_name	Doctor of Philosophy (PhD.)
qualification_level	Doctorate
author	Ak-Kaif, Mohammed Ahmed Imran
author_facet	Ak-Kaif, Mohammed Ahmed Imran
author_sort	Ak-Kaif, Mohammed Ahmed Imran
title	A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
title_short	A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
title_full	A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
title_fullStr	A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
title_full_unstemmed	A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)
title_sort	study on cyp2c19 genetic variations of clopidogrel and ticagrelor treatment among coronary artery disease (cad) patients undergoing percutaneous coronary intervention (pci)
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Farmasi (School of Pharmacy)
publishDate	2023
url	http://eprints.usm.my/60515/1/Pages%20from%20MOHAMMED%20AHMED%20IMRAN%20AK-KAIF%20-%20TESIS.pdf
_version_	1804888953606635520

A Study On Cyp2c19 Genetic Variations Of Clopidogrel And Ticagrelor Treatment Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI)

Similar Items